These studies have been successful in reporting that in human ovarian cancer cell lines and xenograft mouse models COL11A1 is not only associated with poor response to cisplatin, but also confers cisplatin resistance though multiple mechanisms. This evidence concerns the gene COL11A1 and ovarian carcinoma.